Last reviewed · How we verify

NCT03695484: PRIME-AF

Registry Evaluating AF Ablation Techniques

Status unknown Last updated 26 January 2022
What this trial tests

trial in Atrial Fibrillation in 212 participants. Status unknown.

Timeline
31 October 2018
Primary endpoint
9 June 2021
30 June 2022

Quick facts

Lead sponsorErasmus Medical Center
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment212
Start date31 October 2018
Primary completion9 June 2021
Estimated completion30 June 2022
Sites3 locations across Belgium, Netherlands, Russia

Conditions studied

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Atrial Fibrillation or Catheter Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational registry is to prospectively collect procedure efficiency, safety and acute and long term outcome data from catheter ablation procedures as treatment of paroxysmal atrial fibrillation, using the following treatment modalities: * Cryoballoon ablation * Manual guided RF ablation using Contact Force catheters * Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings * Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Erasmus Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03695484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing